We have to look at the science and the data. No matter what the manufacturer says, we can make contingencies for the need for further doses a year beyond this one. We need to have the data to look at the vaccine effectiveness, and to see how people responded to their first and second doses. Then we expect both Health Canada and the National Advisory Committee on Immunization to look at that data in order to provide recommendations.
It is too premature to do that. We have to do epidemiologic studies, look at the variants, and then look at how vaccines may or may not need to be adjusted according to what is circulating at the time.